Willis H. Navarro

1.6k total citations
54 papers, 728 citations indexed

About

Willis H. Navarro is a scholar working on Oncology, Hematology and Pathology and Forensic Medicine. According to data from OpenAlex, Willis H. Navarro has authored 54 papers receiving a total of 728 indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Oncology, 22 papers in Hematology and 15 papers in Pathology and Forensic Medicine. Recurrent topics in Willis H. Navarro's work include Viral-associated cancers and disorders (19 papers), Lymphoma Diagnosis and Treatment (15 papers) and Hematopoietic Stem Cell Transplantation (14 papers). Willis H. Navarro is often cited by papers focused on Viral-associated cancers and disorders (19 papers), Lymphoma Diagnosis and Treatment (15 papers) and Hematopoietic Stem Cell Transplantation (14 papers). Willis H. Navarro collaborates with scholars based in United States, United Kingdom and Canada. Willis H. Navarro's co-authors include Lawrence D. Kaplan, Dennis L. Confer, J. Douglas Rizzo, Brent R. Logan, Hillard M. Lazarus, Fausto R. Loberiza, Koen van Besien, Navneet S. Majhail, Ruta Bajorunaite and Julie M. Vose and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Willis H. Navarro

47 papers receiving 715 citations

Peers

Countries citing papers authored by Willis H. Navarro

Since Specialization

Citations

This map shows the geographic impact of Willis H. Navarro's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Willis H. Navarro with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Willis H. Navarro more than expected).

Fields of papers citing papers by Willis H. Navarro

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Willis H. Navarro. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Willis H. Navarro. The network helps show where Willis H. Navarro may publish in the future.

Co-authorship network of co-authors of Willis H. Navarro

This figure shows the co-authorship network connecting the top 25 collaborators of Willis H. Navarro. A scholar is included among the top collaborators of Willis H. Navarro based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Willis H. Navarro. Willis H. Navarro is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Phase II Trial of nab-Sirolimus in Patients With Advanced Malignant Perivascular Epithelioid Cell Tumors (AMPECT): Long-Term Efficacy and Safety Update 2024 ·Journal of Clinical Oncology ·Andrew J. Wagner, Vinod Ravi, Richard F. Riedel, Kristen N. Ganjoo, Brian A. Van Tine, Rashmi Chugh, Lee D. Cranmer, Erlinda M. Gordon, Jason L. Hornick, Heng Du, Li Ding, Anita N. Schmid, Willis H. Navarro, David J. Kwiatkowski, Mark A. Dickson	16
2	UPLIFT (ENGOT-ov67/GOG-3048): Results from the phase II trial of upifitamab rilsodotin, a NaPi2b-directed dolaflexin antibody-drug conjugate, in platinum-resistant ovarian cancer 2024 ·Gynecologic Oncology ·Debra J. Richardson, Gopa Iyer, Anita Schmid, Norma Alonzo Palma, Willis H. Navarro, Jordi Rodón	1
3	Tabelecleucel for allogeneic haematopoietic stem-cell or solid organ transplant recipients with Epstein–Barr virus-positive post-transplant lymphoproliferative disease after failure of rituximab or rituximab and chemotherapy (ALLELE): a phase 3, multicentre, open-label trial 2024 ·The Lancet Oncology ·Kris M. Mahadeo, Robert A. Baiocchi, Amer Beitinjaneh, Sridhar Chaganti, Sylvain Choquet, Daan Dierickx, Rajani Dinavahi, (unknown), Laurence Gamelin, Armin Ghobadi, Norma Guzmán‐Becerra, Manher Joshi, Aditi Mehta, Willis H. Navarro, Sarah Nikiforow, Richard J. O’Reilly, Ran Reshef, (unknown), Tassja J. Spindler, Susan E. Prockop	35
4	TP004/#1561 A phase 2, open-label, single-arm, prospective, multicenter study of nab -sirolimus plus letrozole in advanced or recurrent endometrioid endometrial cancer 2024 ·(unknown), Fernanda Musa, Cara Mathews, Nick M. Spirtos, Brian M. Slomovitz, Anna Priebe, Angela Green, (unknown), Michael J. Birrer, Thomas J. Herzog, Li Ding, Anita Schmid, Willis H. Navarro, (unknown)	0
5	Phase 2, multicenter, open-label basket trial of nab-sirolimus for patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes (PRECISION I) (1300) 2023 ·Gynecologic Oncology ·Elizabeth Lee, Jordi Rodón, Michael J. Demeure, Dustin A. Deming, Noah Federman, Meredith McKean, Alexander I. Spira, David J. Kwiatkowski, Maen Hussein, Erlinda M. Gordon, David K. Crockett, Kristen N. Ganjoo, (unknown), Lee D. Cranmer, Anita Schmid, Willis H. Navarro, Loretta M. Itri, Gopa Iyer	1
6	Phase 2, multicenter, open-label basket trial of nab-sirolimus for patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes (PRECISION I). 2023 ·Journal of Clinical Oncology ·Gopa Iyer, Michael J. Demeure, Dustin A. Deming, Noah Federman, Meredith McKean, (unknown), Alexander I. Spira, David J. Kwiatkowski, Maen Hussein, Erlinda M. Gordon, David G. Crockett, Kristen N. Ganjoo, (unknown), (unknown), Anita N. Schmid, Willis H. Navarro, Loretta M. Itri	0
7	Phase 2, multicenter, open-label basket trial of nab-sirolimus for patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes (PRECISION I). 2023 ·Journal of Clinical Oncology ·Dustin A. Deming, Jordi Rodón, Michael J. Demeure, Noah Federman, Meredith McKean, (unknown), Alexander I. Spira, David J. Kwiatkowski, Maen Hussein, Erlinda M. Gordon, David G. Crockett, Kristen N. Ganjoo, (unknown), (unknown), Anita N. Schmid, Willis H. Navarro, Loretta M. Itri, Gopa Iyer	1
8	29P ALLELE study: A multicenter, open label, phase III study of tabelecleucel for solid organ or allogeneic hematopoietic cell transplant subjects with Epstein-Barr virus-driven post-transplant lymphoproliferative disease (EBV+ PTLD) after failure of rituximab or rituximab and chemotherapy 2020 ·Annals of Oncology ·Nina Worel, Josè Antonio Pérez-Simón, Pere Barba, Daan Dierickx, Minoti Hiremath, (unknown), Laurence Gamelin, Willis H. Navarro, Sylvain Choquet	0
9	Risks and Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation for Hematologic Malignancies in Patients with HIV Infection 2019 ·Biology of Blood and Marrow Transplantation ·Shukaib Arslan, Mark R. Litzow, Nathan W. Cummins, Stacey A. Rizza, Andrew D. Badley, Willis H. Navarro, Shahrukh K. Hashmi	10
10	Efficacy and Safety of ATA129, Partially Matched Allogeneic Third-Party Epstein-Barr Virus-Targeted Cytotoxic T Lymphocytes in a Multicenter Study for Post-Transplant Lymphoproliferative Disorder 2018 ·Biology of Blood and Marrow Transplantation ·Susan E. Prockop, (unknown), Robert A. Baiocchi, Nancy Bunin, Kris M. Mahadeo, Eneida R. Nemecek, Sarah Nikiforow, Ran Reshef, Donald E. Tsai, Willis H. Navarro, Richard J. O’Reilly	6
11	Challenges and Potential Solutions for Recruitment and Retention of Hematopoietic Cell Transplantation Physicians: The National Marrow Donor Program’s System Capacity Initiative Physician Workforce Group Report 2014 ·Biology of Blood and Marrow Transplantation ·Linda J. Burns, James Gajewski, Navneet S. Majhail, Willis H. Navarro, Miguel‐Angel Perales, Evan Shereck, George B. Selby, Edward L. Snyder, Ann E. Woolfrey, Mark R. Litzow	12
12	Unrelated adult stem cell donor medical suitability: recommendations from the World Marrow Donor Association Clinical Working Group Committee 2014 ·Bone Marrow Transplantation ·Robert Lown, (unknown), Willis H. Navarro, Suzanna M. van Walraven, (unknown), Mirjam Fechter, Rachel Pawson, Mats Bengtsson, Meral Beksaç, Stephen K. Field, Hung‐Chih Yang, Bronwen E. Shaw	26
13	Lower risk for serious adverse events and no increased risk for cancer after PBSC vs BM donation 2014 ·Blood ·Michael A. Pulsipher, Pintip Chitphakdithai, Brent R. Logan, Willis H. Navarro, John E. Levine, J. Philip Miller, Bronwen E. Shaw, Paul V. O’Donnell, Navneet S. Majhail, Dennis L. Confer	73
14	Towards a global system of vigilance and surveillance in unrelated donors of haematopoietic progenitor cells for transplantation 2013 ·Bone Marrow Transplantation ·Bronwen E. Shaw, Joab Chapman, Mirjam Fechter, Lydia Foeken, Hildegard Greinix, William Ying Khee Hwang, (unknown), Matti Korhonen, (unknown), Willis H. Navarro, Jeff Szer	8
15	National Marrow Donor Program Session: Donor Issues 2012 ·Biology of Blood and Marrow Transplantation ·Willis H. Navarro, Galen E. Switzer, Michael A. Pulsipher	8
16	Obesity Does Not Preclude Safe and Effective Myeloablative Hematopoietic Cell Transplantation (HCT) for Acute Myelogenous Leukemia (AML) in Adults 2010 ·Biology of Blood and Marrow Transplantation ·Willis H. Navarro, Afiba Manza‐A. Agovi, Brent R. Logan, Karen K. Ballen, Brian J. Bolwell, Haydar Frangoul, Vikas Gupta, Theresa Hahn, Vincent T. Ho, Mark Juckett, Hillard M. Lazarus, Mark R. Litzow, Jane L. Liesveld, Jan S. Moreb, David I. Marks, Philip L. McCarthy, Marcelo C. Pasquini, J. Douglas Rizzo	61
17	Selection of Adult Unrelated Hematopoietic Stem Cell Donors: Beyond HLA 2009 ·Biology of Blood and Marrow Transplantation ·Dennis L. Confer, Linda Abress, Willis H. Navarro, J. Alejandro Madrigal	20
18	Effect of Body Mass Index on Mortality of Patients with Lymphoma Undergoing Autologous Hematopoietic Cell Transplantation 2006 ·Biology of Blood and Marrow Transplantation ·Willis H. Navarro, Fausto R. Loberiza, Ruta Bajorunaite, Koen van Besien, Julie M. Vose, Hillard M. Lazarus, J. Douglas Rizzo	79
19	Impact of obesity in the setting of high-dose chemotherapy 2003 ·Bone Marrow Transplantation ·Willis H. Navarro	33
20	Autologous stem cell transplantation for acute myeloid leukemia in first remission 2000 ·Biology of Blood and Marrow Transplantation ·Charles Linker, Curt A. Ries, Lloyd E. Damon, Peter H. Sayre, Willis H. Navarro, Hope S. Rugo, Arnold D. Rubin, Delvyn C. Case, Pamela Crilley, David Topolsky, Isadore Brodsky, (unknown), Jeffrey L. Wolf	45

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact